IN-VIVO ANALYSIS OF DISEASE-MODIFYING DRUG-THERAPY ACTIVITY IN RHEUMATOID-ARTHRITIS BY SEQUENTIAL IMMUNOHISTOLOGICAL ANALYSIS OF SYNOVIAL-MEMBRANE INTERLEUKIN-1-BETA

Citation
Bw. Kirkham et al., IN-VIVO ANALYSIS OF DISEASE-MODIFYING DRUG-THERAPY ACTIVITY IN RHEUMATOID-ARTHRITIS BY SEQUENTIAL IMMUNOHISTOLOGICAL ANALYSIS OF SYNOVIAL-MEMBRANE INTERLEUKIN-1-BETA, Journal of rheumatology, 21(9), 1994, pp. 1615-1619
Citations number
15
Categorie Soggetti
Rheumatology
Journal title
ISSN journal
0315162X
Volume
21
Issue
9
Year of publication
1994
Pages
1615 - 1619
Database
ISI
SICI code
0315-162X(1994)21:9<1615:IAODDA>2.0.ZU;2-J
Abstract
Objective. To assess sequential changes of synovial membrane interleuk in 1 beta (IL-1 beta) in patients with rheumatoid arthritis receiving chrysotherapy and glucocorticoids. Methods. Sequential synovial biopsi es taken before and after 2 and 12 weeks of treatment were analyzed by immunohistological techniques. Results. Significant decreases in IL-1 beta staining occurred in biopsies taken after 12 weeks' chrysotherap y, while mononuclear cell numbers were unchanged. Results were similar in patients receiving glucocorticoid and gold, and in those receiving gold alone. Conclusion. These data suggest that chrysotherapy reduces IL-1 beta production in vivo, a property that has been shown in vitro , and that this change precedes changes in synovial membrane mononucle ar cell numbers.